Cancer-Sensitizing Composition for Drug-Resistant Tumor Treatment

The patent uses targeted anticancer drugs that specifically recognize and bind to unique molecular markers on cancer cell surfaces, delivering cytotoxic effects locally to cancer cells while leaving normal cells unaffected. This selective targeting approach maintains high anticancer efficacy while minimizing damage to healthy rapidly-differentiating cells.

The patent introduces targeted delivery systems such as antibody-drug conjugates and nanocarriers that act as intermediaries between the drug and cancer cells. These intermediaries selectively transport anticancer agents to cancer cell surfaces through specific molecular recognition, preventing direct exposure of normal cells to toxic drugs while ensuring concentrated drug delivery at the cancer site.

The patent combines multiple targeted anticancer drugs with different mechanisms of action into combination therapies. By simultaneously targeting multiple distinct molecular pathways involved in cancer growth and survival, this approach prevents cancer cells from developing resistance through single genetic mutations, as evidenced by clinical responses in patients with advanced cancers who have exhausted single-agent options.

The patent employs adaptive targeted therapy approaches where treatment targets are dynamically adjusted based on evolving cancer cell characteristics. Through sequential targeting of different molecular alterations that arise during cancer progression and treatment, the therapy remains effective against resistant clones while maintaining selectivity for cancer cells over normal cells.